ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (9)
2021
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
British Journal of Haematology
-
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia
Leukemia Research, Vol. 85
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
2009
-
International prognostic scoring system for Waldenström macroglobulinemia
Blood, Vol. 113, Núm. 18, pp. 4163-4170
2008
-
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225
2006
-
Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia
Blood, Vol. 107, Núm. 9, pp. 3442-3446